What changed?
A sourced timeline of research records and material development changes tracked by BACToBasics for Tirzepatide. Research-publication dates and clinical-development event dates are labeled separately so they are not mistaken for the same type of update.
Tracked items
3
Research sources
2
Development entries
1
Latest recorded date
Dec 20, 2024
Latest development activity
Dec 20, 2024 · Approval · Approved · United States
FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, expanding tirzepatide's approved clinical context.
Open source ↗Latest research record by publication date
Published 2024 · Regulatory · Regulatory / approval
FDA approval expanded Zepbound's clinical context to include moderate-to-severe obstructive sleep apnea in adults with obesity.
Open source ↗Tracked timeline
Development changes are dated to the underlying milestone. Research-source entries use the study or source publication year currently stored in the Research Library; that year is not presented as the date BACToBasics added the record.
Approval · Approved · United States
FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, expanding tirzepatide's approved clinical context.
Regulatory · Regulatory / approval
FDA approval expanded Zepbound's clinical context to include moderate-to-severe obstructive sleep apnea in adults with obesity.
Human intervention · Randomized controlled trial
SURMOUNT-1 provided large randomized human evidence for tirzepatide in chronic weight management.
Following a compound creates a clean baseline from the updates currently known. When BACToBasics later records a new research source or material development change, the My Tools update badge can surface it as new for you.
BACToBasics provides educational research organization only. A development milestone does not predict future approval, and a research record does not establish that a compound is safe, effective, approved, or appropriate for use.